| Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma LJ Costa, S Chhabra, E Medvedova, BR Dholaria, TM Schmidt, KN Godby, ... Journal of Clinical Oncology 40 (25), 2901-2912, 2022 | 167 | 2022 |
| International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials LJ Costa, BA Derman, S Bal, S Sidana, S Chhabra, R Silbermann, JC Ye, ... Leukemia 35 (1), 18-30, 2021 | 87 | 2021 |
| Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis S Giri, A Grimshaw, S Bal, K Godby, P Kharel, B Djulbegovic, ... JAMA oncology 6 (11), 1759-1765, 2020 | 83 | 2020 |
| Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma A Lesokhin, S Bal, A Badros Cancer Immunology Research 2019 (7), 1224–9, 2019 | 33 | 2019 |
| Clinical activity of BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T cell therapy, in patients … S Bal, MH Kocoglu, O Nadeem, M Htut, T Gregory, LD Anderson, LJ Costa, ... Blood 140 (Supplement 1), 883-885, 2022 | 29 | 2022 |
| Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancer A Santra, S Bal, S Mahargan, C Bal Nuclear medicine communications 32 (1), 52-58, 2011 | 29 | 2011 |
| Stem cell mobilization yields with daratumumab-and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and … S Chhabra, N Callander, NL Watts, LJ Costa, B Thapa, JL Kaufman, ... Transplantation and Cellular Therapy 29 (3), 174. e1-174. e10, 2023 | 27 | 2023 |
| Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma M Mohan, R Chakraborty, S Bal, A Nellore, M Baljevic, A D'Souza, ... British Journal of Haematology 203 (5), 736-746, 2023 | 22 | 2023 |
| Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial LJ Costa, S Chhabra, E Medvedova, BR Dholaria, TM Schmidt, KN Godby, ... The Lancet Haematology 10 (11), e890-e901, 2023 | 21 | 2023 |
| Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies S Bal, E Malek, A Kansagra, SZ Usmani, R Vij, KN Godby, RF Cornell, ... Leukemia 36 (3), 877-880, 2022 | 21 | 2022 |
| Multiple myeloma with t (11; 14): unique biology and evolving landscape S Bal, SK Kumar, R Fonseca, F Gay, VTM Hungria, A Dogan, LJ Costa American Journal of Cancer Research 12 (7), 2950, 2022 | 21 | 2022 |
| Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma S Bal, A Weaver, RF Cornell, LJ Costa British Journal of Haematology, https://doi.org/10.1111/bjh.16130, 2019 | 21 | 2019 |
| Potential of F-18 PET/CT in the detection of leptomeningeal metastasis RG Short, S Bal, JP German, RJ Poelstra, A Kardan The Neuroradiology Journal 27 (6), 685-689, 2014 | 21 | 2014 |
| Analysis of transplant-eligible patients (Pts) who received frontline daratumumab (DARA)-Based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM … N Callander, R Silbermann, JL Kaufman, KN Godby, JP Laubach, ... Blood 140 (Supplement 1), 10144-10147, 2022 | 17 | 2022 |
| Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials. S Giri, A Grimshaw, S Bal, KN Godby, P Kharel, B Djulbegovic, SZ Usmani, ... Journal of Clinical Oncology 38 (15_suppl), 8540-8540, 2020 | 16 | 2020 |
| Outcomes of autologous hematopoietic cell transplantation in diffuse large B cell lymphoma refractory to firstline chemoimmunotherapy S Bal, LJ Costa, C Sauter, C Litovich, M Hamadani Transplantation and cellular therapy 27 (1), 55. e1-55. e7, 2021 | 13 | 2021 |
| AL amyloidosis: untangling new therapies S Bal, H Landau Hematology 2021 (1), 682-688, 2021 | 10 | 2021 |
| Outcomes of MRD-adapted treatment modulation in patients with newly diagnosed multiple myeloma receiving daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) and … LJ Costa, S Chhabra, E Medvedova, TM Schmidt, B Dholaria, KN Godby, ... Blood 140 (Supplement 1), 7275-7277, 2022 | 9 | 2022 |
| Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted consolidation and treatment cessation. Final primary … LJ Costa, S Chhabra, NS Callander, E Medvedova, B Dholaria, ... Blood 138, 481, 2021 | 9 | 2021 |
| New regimens and directions in the management of newly diagnosed multiple myeloma S Bal, S Giri, KN Godby, LJ Costa American Journal of Hematology 96 (3), 367-378, 2021 | 9 | 2021 |
